Raymond James raised the firm’s price target on AxoGen (AXGN) to $18, while keeping an Outperform rating on the shares. The firm appreciates that expectations were high heading into Q3, but saw nothing in the Q3 results and views the selloff in the shares as “excessive.” Raymond James further sees Q3 as evidence that this business can sustainably grow revenue in the teens with an improving, and attractive, profit profile. The firm also believes the new CEO Mike Dale is the right person to drive this progress.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXGN:
- AxoGen trading resumes
- AxoGen trading halted, volatility trading pause
- AxoGen Reports Strong Q3 2024 Revenue Growth
- AxoGen reports Q3 adjusted EPS 7c, consensus 1c
- AxoGen reiterates FY24 revenue view of $182M-$186M, consensus $184.72M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
